Rockpointe is launching its 2019 Clinical Updates in Oncology, an engaging set of CME/CE oncology conferences designed to make oncologists, nurses, and the entire oncology team aware of recently updated guidelines and emerging clinical-trial data and help clinicians integrate the latest treatment options into the care of their patients. The conferences will be held at the University of Utah in Salt Lake City on Feb. 23 starting at 8:45am Mountain, and at Northwestern University in Chicago on March 9 starting at 8:45am Central. The Utah conference will also be simulcast online live throughout the country. Divided into four sessions, each conference will cover the following topics: gastric and gastroesophageal cancer, myelofibrosis, breast cancer, and leukemia.
Session 1: Gastric and GEJ cancer
The recent inclusion of targeted biologic agents in guideline recommendations increases the complexity of treatment selections and appropriate sequencing of treatments for patients with gastric and gastroesophageal (GEJ) cancers. Integrating New Therapies into Treatment Regimens for Gastric and Gastroesophageal Cancer will guide community clinicians in making consistent, evidence-based management choices with treatments that are appropriately sequenced. Participants will also learn how to manage possible treatment side effects and to integrate emerging therapies into treatment regimens as new clinical trial data mature.
This activity, supported by an educational grant from Lilly, is intended for community-based medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and the rest of the multidisciplinary cancer care team for gastric and GEJ cancers. Successful completion of this CME activity, which includes participation in the evaluation component, enables participants to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Session 2: Myelofibrosis
Clinicians who treat patients with myelofibrosis and other myeloproliferative neoplasms (MPNs) face significant clinical challenges; increased awareness of best practices can help them manage MPNs during treatment selection and remediate treatment-emergent side effects. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions will discuss guidelines that support consistent decision-making for appropriate treatment of MPNs, including considerations for the management of cytopenias and other possible complications. The program will increase awareness of emerging clinical study data and explore the potential to optimize treatments via patient referrals to recruiting clinical trials.
This activity, supported by educational grants from Celgene Corporation and Incyte, is intended for hematologists, oncologists, and other members of the oncology care team involved in the care of patients with MPNs.
Session 3: Breast cancer
The emergence and approval of several CDK 4/6 inhibitors and everolimus, an mTOR inhibitor, warrant an assessment of new and emerging data to determine which agents should be used in specific patients with differing menopausal statuses and treatment outcomes goals. Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer will frame treatment decisions within the context of patient cases to facilitate care that is consistent with recently updated clinical guidelines and consensus recommendations. Guidance will also be provided to appropriately integrate PI3K/Akt/mTOR and CDK 4/6 targeted therapies into clinical practice for optimal personalized medicine for pre-, peri-, and post-menopausal HR+/HER2- breast cancer patients.
This activity, supported by educational grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly, is intended for community-based medical oncologists and other clinicians involved in the care of patients with advanced or metastatic breast cancer.
Session 4: Leukemia
Innovative therapies that are recently FDA-approved or in the later stages of clinical development are revolutionizing options for effective care in leukemia patients. Clinicians must have a heightened awareness of these rapid advancements and novel therapeutic options to best manage leukemia cases and improve patient outcomes. Optimizing the Use of Novel Agents for the Treatment of Leukemia will guide clinicians in the integration of new data into clinical practice through case-based discussions and an emphasis on patient communication. This program is designed to increase awareness of novel treatment options and allow clinicians to appropriately incorporate new data into the management of their leukemia patients.
This activity, supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer, is intended for community-based hematologists/oncologists and other clinicians involved in the care of patients with leukemia.
Certification for the four sessions will be provided by the Potomac Center for Medical Education (PCME) and the Global Education Group. Each activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) and American Nurses Credentialing Center (ANCC). Care teams will be able to claim up to four hours of credit and the program in Utah will be webcast live throughout the country.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MACRA, combating the nation’s opioid crisis, and utilizing technical advances that improve care. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.
To register for these events: https://www.rockpointe.com/clinical-updates-oncology/